ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06855 ASCENTAGE-B

Not Yet Opened 01-28 16:08:16

49.300

-0.140

-0.28%

High50.200	Low48.960	Vol1.43M
Open49.700	D1 Closing49.440	Amplitude2.51%
Mkt Cap18.39B	Tradable Cap18.39B	Total Shares373.00M
T/O70.90M	T/O Rate0.38%	Tradable Shares373.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"ASCENTAGE-B","latestPrice":49.3,"timestamp":1769587696006,"preClose":49.44,"halted":0,"volume":1434200,"delay":0,"changeRate":-0.0028317152103559985,"floatShares":373000000,"shares":373000000,"eps":-1.342217,"marketStatus":"Not Yet Opened","change":-0.14,"latestTime":"01-28 16:08:16","open":49.7,"high":50.2,"low":48.96,"amount":70901699,"amplitude":0.025081,"askPrice":49.3,"askSize":7900,"bidPrice":49.24,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.405,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769650200000},"marketStatusCode":0,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":49.44,"openAndCloseTimeList":[[1769563800000,1769572800000],[1769576400000,1769587200000]],"volumeRatio":0.851297,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855/tweets","defaultTab":"tweets","newsList":[{"id":"2603629889","title":"Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603629889","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603629889?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:25","pubTimestamp":1768440322,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbJhWXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","06855","BK1161","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","SG9999014039.USD","LU0314104364.USD","BK1574","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","BK4112"],"gpt_icon":0},{"id":"2602396695","title":"A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2602396695","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602396695?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:17","pubTimestamp":1768054675,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies.\nSee our latest analysis for Ascentage Pharma Group International.\nThe FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4129","APG","06855","BK1161","IND","BK1574","LU2125909759.SGD","LU2125909916.SGD","LU1923622291.USD"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2125909916.SGD","LU1923622291.USD","BK1161","APG","BK4129","LU2125909759.SGD","06855","AAPG","BK1574"],"gpt_icon":0},{"id":"2601844717","title":"FDA Clears IND for Ascentage Pharma’s BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844717","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844717?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747615,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has received Investigational New Drug  clearance from the U.S. Food and Drug Administration  for its novel next-generation Bruton tyrosine kinase -targeted protein degrader, APG-3288. This regulatory approval enables the company to initiate a global, multicenter Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed or refractory B-cell malignancies. The clearance marks a significant milestone in Ascentage Pharma’s efforts to expand its pipeline of innovative therapies for hematologic malignancies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content use","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4qKXD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD","BK1161","SG9999014039.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","BK4585","06855","BK4112","NDAQ","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2601844774","title":"Ascentage Pharma Announces Ind Clearance by the U.S. Food and Drug Administration for Btk Degrader Apg-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844774?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA4NDY9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"gpt_icon":0},{"id":"2595713514","title":"Ascentage Pharma Group International Files Director List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713514","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713514?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:46","pubTimestamp":1767105999,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL4Nw1Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2595713803","title":"Ascentage Pharma Appoints Dr. Debra Yu to Nomination Committee and Dr. David Sidransky as Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713803","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713803?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:42","pubTimestamp":1767105768,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has announced changes to its board and committees. Dr. Debra Yu has been appointed as an additional member of the Nomination Committee, which will now include Dr. David Sidransky as chairman, along with Mr. Ren Wei and Marc E. Lippman. The company also announced the establishment of a Research and Development Committee and the appointment of a Lead Independent Non-Executive Director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5thV3d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2593312020","title":"Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2593312020","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593312020?lang=en_us&edition=fundamental","pubTime":"2025-12-21 20:17","pubTimestamp":1766319425,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the story behind the stock.\nSee our latest analysis for Ascentage Pharma Group International.\nThe latest ASH data land after a bumpy stretch, with a 30 day share price return of minus 11.8 percent and a 90 day share price return of minus 25.1 percent. However, a much stronger year to date share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2463526074.USD","ASH","BK1161","06855","BK4109","BK1574"],"gpt_icon":0},{"id":"2592990948","title":"Ascentage Pharma to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990948","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990948?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976500,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company's presentation is scheduled for Wednesday, January 14, 2026, at 2:15 p.m. PT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on December 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL3kLYZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","SG9999014013.SGD","BK1574","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4585","BK1161","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","06855","BK4112"],"gpt_icon":0},{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06855","BK1574","AAPG","BK4139"],"gpt_icon":0},{"id":"2591138655","title":"Is Ascentage Pharma Group International Pricing In Too Much Biotech Optimism After Big 3 Year Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591138655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591138655?lang=en_us&edition=fundamental","pubTime":"2025-12-14 00:26","pubTimestamp":1765643210,"startTime":"0","endTime":"0","summary":"If you are wondering whether Ascentage Pharma Group International is still a smart way to get exposure to biotech upside, you are not alone. That is exactly what we are going to unpack here.\nDespite a choppy recent stretch, with the share price down 6.8% over the last week and 8.1% over the past month, the stock is still sitting on gains of 35.4% year to date and 53.1% over the last year, building on a 131.9% return over three years.\nRecent moves have been shaped less by day to day trading...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-pricing-in-too-much","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-pricing-in-too-much","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","DCF","BK1574","06855"],"gpt_icon":0},{"id":"2590341368","title":"Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341368","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341368?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:31","pubTimestamp":1765287079,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has presented updated clinical data on Olverembatinib, its novel therapy for second-line treatment of chronic myeloid leukemia in chronic-phase , at the 67th American Society of Hematology  Annual Meeting. The results showed a 76.7% complete cytogenetic response rate in patients who had failed first-line therapy with second-generation tyrosine kinase inhibitors . Molecular responses deepened with extended treatment duration, with a major molecular response rate reaching 60% at 21 cycles. The company reported that the efficacy data support the potential for advancing Olverembatinib to earlier lines of treatment for a broader patient population. The findings presented were updates from results previously released at ASH 2024 and included longer follow-up data on efficacy and safety.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL6Xy697:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2589353553","title":"Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353553","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353553?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:02","pubTimestamp":1765198928,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has announced the presentation of pivotal data from a China registrational Phase II study of Lisaftoclax  monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma  who were refractory to Bruton's tyrosine kinase inhibitors . The results, which were presented in an oral report at the 2025 American Society of Hematology  Annual Meeting, showed that Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated, BTKi-refractory patients, nearly half of whom had complex karyotype. The study also reported a median progression-free survival of 23.89 months, with no cases of tumor lysis syndrome observed. The data supported the new drug application  approval of Lisaftoclax by China's National Medical Products Administration in July 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7jyM40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2589487019","title":"Revisiting Ascentage Pharma Group International (SEHK:6855)’s Valuation After Its Strong One-Year Share Price Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589487019?lang=en_us&edition=fundamental","pubTime":"2025-12-07 16:19","pubTimestamp":1765095588,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) has quietly outperformed over the past year, and with shares up roughly 56% in that time, investors are starting to revisit the story behind this clinical stage biotech.\nSee our latest analysis for Ascentage Pharma Group International.\nThe stock has been choppy in recent months, with a 1 day share price return of 4.44 percent and a 90 day share price return of minus 19.91 percent. However, a 1 year total shareholder return of 55.76 percent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/revisiting-ascentage-pharma-group-international-sehk6855s-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/revisiting-ascentage-pharma-group-international-sehk6855s-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2589502058","title":"BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589502058","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589502058?lang=en_us&edition=fundamental","pubTime":"2025-12-05 11:51","pubTimestamp":1764906718,"startTime":"0","endTime":"0","summary":"BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment** Shares of Ascentage Pharma Group International 6855.HK rise 6.8% to HK$65, their highest level since November 27** Stock on track for the biggest one-day pct gain since August 5 ** Ascentage receives clearance from US FDA and European Medicines Agency for a phrase III  study of its blood cancer drug olverembatinib** The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with certain types of leukemia ** Stock up 37% YTD; Hang Seng Biotech Index .HSBIO up 78.8%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL1N3XB02Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","06855","EMA","BK4081","BK1161","BK4139","BK1574"],"gpt_icon":0},{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","06855","III","BK4588","LU1571399168.USD","BK4533","BK1574","ALL","BK4585","LU0985320562.USD","LU1699723380.USD","BK1161","BK4107","AAPG","BK4139","LU2355687059.USD","BK4081","BK4134"],"gpt_icon":0},{"id":"1141783167","title":"Ascentage Pharma (6855) Announces Global Phase III Study Clearance for Olverembatinib in First-Line Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1141783167","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141783167?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:04","pubTimestamp":1764893094,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (Ascentage Pharma, stock code: 6855) reported that it has received regulatory clearance from both the US Food and Drug Administration (FDA) and the European...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"2589685569","title":"Ascentage Pharma Group International - Global Registrational Phase Iii Study of Olverembatinib Cleared by FDA and Ema","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589685569?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:57","pubTimestamp":1764892668,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06855","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0287},{"period":"1month","weight":-0.0776},{"period":"3month","weight":-0.252},{"period":"6month","weight":-0.3133},{"period":"1year","weight":0.4126},{"period":"ytd","weight":-0.0538}],"compareEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.095},{"period":"1year","weight":0.3431},{"period":"ytd","weight":0.0584}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.087899},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.035469},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.10554},{"month":4,"riseRate":0.833333,"avgChangeRate":0.119495},{"month":5,"riseRate":0.5,"avgChangeRate":0.054537},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"ASCENTAGE-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCENTAGE-B,06855,ASCENTAGE-B股票,ASCENTAGE-B股票老虎,ASCENTAGE-B股票老虎国际,ASCENTAGE-B行情,ASCENTAGE-B股票行情,ASCENTAGE-B股价,ASCENTAGE-B股市,ASCENTAGE-B股票价格,ASCENTAGE-B股票交易,ASCENTAGE-B股票购买,ASCENTAGE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}